Table 2.

Combined included study characteristics

Demographics
Total Participants (% Female)	1,056 (56.9)
Mean Age	73.5
Diagnosis and Severity
Cognitive Diagnostic Criteria Utilised	NINCDS‐ADRDA (n = 8) Peterson MCI Criteria (n = 3) Albert Criteria (n = 1) DSM‐IV (n = 1) DSM‐V (n = 1) DSM‐V and Peterson MCI Criteria (n = 1) Mayo Clinic Criteria (n = 1)
Assessment of Dementia Severity Tool	MMSE (n = 10) MoCA (n = 2) CDR (n = 2) TDAS (n = 1) Not reported (n = 1)a
Baseline Cognitive Scores by Tool	Mean MMSE 22.38/30 (n = 9) Median MMSE 28/30 (n = 1) Mean MOCA 21.93/30 (n = 2) Mean CDR 1.38 (n = 2) Mean TDAS 7.57 (n = 1)
Sleep Co‐Morbidity Status	Sleep Disorders Included:‐ Mixed Population ± Sleep Disorder (n = 5) OSA (n = 2) Insomnia by DSM V Criteria (n = 2) Clinically determined ‘Alteration to Sleep Pattern’ (n = 1) Sleep Disorders Excluded:‐ All (n = 2) Self‐Reported Sleep‐Wake Disturbance (n = 1) Moderate‐Severe Sleep Disturbance (n = 1) Circadian Rhythm Disorders and OSA (n = 1) Significantly Reduced SWS (n = 1)
Comparison
Methodology Used	Placebo Groups (n = 4) Active Non‐Pharmacological Control Groups (n = 3) Non‐Treatment Arms (n = 2) Placebo Crossover Designs (n = 5) Healthy Population Group (n = 1) Multiple Treatment Arms (n = 1)
Outcome
Measurement Tools	Polysomnography (n = 8) Wrist Actigraphy (n = 4) PSQI (n = 6) ESS (n = 2) FOSQ (n = 1) ISI (n = 1)
Outcome Measure (Tool Utilised)	TST (Polysomnography n = 6, Actigraphy n = 3, PSQI n = 2) SE (Polysomnography n = 6, Actigraphy n = 3, PSQI n = 2) WASO (Polysomnography n = 5, Actigraphy n = 3) SL (Polysomnography n = 6, Actigraphy n = 2, PSQI n = 2) % REM, N1, N2, N3/N4 Sleep Duration (Polysomnography n = 7) AI (Polysomnography n = 4) PSQI Total (PSQI n = 6) Other e.g. PLMI, AH, Transition, TWT, Spindle Characteristics and REM Characteristics (Polysomnography n = 4)

^a Diagnosis of MCI made utilising peterson criteria.